RxDoctor Payments Data

Jonathan McFadden, DO

Internal Medicine · Westerville, OHNPI 1083057418

Payments from drug & device makers

$12,144in general payments, 2019–2025

Across 705 payments — averaging $17.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • AbbVie$1K
  • Lilly USA, LLC$1K
  • Amgen$741
  • Pfizer$716
  • AstraZeneca$688
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$12,07599%
  • Education$691%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk112$1,688
AbbVie104$1,419
Lilly USA, LLC61$1,072
Amgen42$741
Pfizer44$716
AstraZeneca(2 entities)31$688
Xeris Pharmaceuticals, Inc.36$678
Abbott23$450
Boehringer Ingelheim24$384
Novartis23$380
Bayer17$357
Exact Sciences14$325
Johnson & Johnson18$320
Sanofi-aventis U.S. LLC16$283
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC17$228
Corcept Therapeutics10$211
Medtronic(2 entities)4$181
Radius Health, Inc.8$174
Dexcom, Inc.7$136
E.r. Squibb & Sons, L.L.C.8$136
Merck9$130
GSK6$114
Biohaven Pharmaceutical Holding Company Ltd.6$95
Cequr Corporation3$92
Phathom Pharmaceuticals, Inc.4$80
Amneal Pharmaceuticals LLC4$76
Actelion Pharmaceuticals US, Inc.3$74
Esperion Therapeutics, Inc.5$71
Sanofi Pasteur Inc.3$65
QOL Medical, LLC3$55
Ascendis Pharma Endocrinology Inc2$48
Astellas Pharma US Inc2$41
Axsome Therapeutics, Inc.2$41
Edwards Lifesciences2$38
Idorsia Pharmaceuticals US Inc2$32
IBSA Pharma Inc.2$31
Laborie Medical Technologies Corp.1$30
Kowa Pharmaceuticals America, Inc.2$28
Boston Scientific1$28
Tempus AI, Inc1$26
Biohaven Pharmaceuticals, Inc.2$24
Ultragenyx Pharmaceutical Inc.1$24
Otsuka America Pharmaceutical, Inc.1$23
Sequel Med Tech, LLC1$22
Recordati_rare_diseases_inc.1$20
Sumitomo Pharma America, Inc.1$20
Ascensia Diabetes Care US Inc.1$19
Lucid Diagnostics Inc.1$19
Dynavax Technologies Corporation1$18
Teleflex LLC1$18
Irhythm Technologies, Inc.1$17
Zealand Pharma US, Inc.1$17
Clarus Therapeutics Inc.1$16
Amryt Pharma Holdings Ltd1$16
ARS Pharmaceuticals Operations, Inc.1$15
Amphastar Pharmaceuticals, Inc.1$15
Kyowa Kirin, Inc.1$15
Insulet Corporation1$15
Shield Therapeutics Inc1$14
Endo Pharmaceuticals Inc.1$14

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$12,144 in reported general payments places this provider in the 95th percentile of 4,428 internal medicine providers in Ohio.

See all internal medicine providers in Ohio

Medicare billing

Part B allowed, 2024
$138,449
Medicare patients
203
Services billed
3,923

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban102$112,624
JardianceEmpagliflozin88$81,870
OzempicSemaglutide70$74,763
RybelsusSemaglutide30$39,438
JanuviaSitagliptin Phosphate20$32,197
TradjentaLinagliptin25$20,343
FarxigaDapagliflozin Propanediol23$18,977
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog31$15,811
XareltoRivaroxaban19$15,681
MyrbetriqMirabegron15$11,778
Breo ElliptaFluticasone/Vilanterol20$11,024
Breztri AerosphereBudesonide/Glycopyr/Formoterol16$10,125
GlyxambiEmpagliflozin/Linagliptin12$7,212
ShingrixVaricella-Zoster Ge/As01b/Pf30$6,531
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,591

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,688$114,201100 claims
PfizerEliquis, Paxlovid$716$114,054115 claims
Boehringer IngelheimJardiance, Tradjenta, Glyxambi$384$109,425125 claims
MerckJanuvia$130$32,19720 claims
AstraZenecaFarxiga, Breztri Aerosphere$688$29,10239 claims
GSKBreo Ellipta, Shingrix, Anoro Ellipta$114$23,14662 claims
Johnson & JohnsonXarelto$320$15,68119 claims
Astellas Pharma US IncMyrbetriq$41$11,77815 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$76$1,721215 claims
AbbVieSynthroid$1,419$1,70516 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,428 internal medicine providers in Ohio.

Other internal medicine in Westerville

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →